Glenmark Pharmaceuticals Limited

NSEI:GLENMARK Stock Report

Market Cap: ₹427.4b

Glenmark Pharmaceuticals Future Growth

Future criteria checks 3/6

Glenmark Pharmaceuticals is forecast to grow earnings and revenue by 64% and 9.2% per annum respectively. EPS is expected to grow by 66.2% per annum. Return on equity is forecast to be 18.3% in 3 years.

Key information

64.0%

Earnings growth rate

66.2%

EPS growth rate

Pharmaceuticals earnings growth17.6%
Revenue growth rate9.2%
Future return on equity18.3%
Analyst coverage

Good

Last updated18 Feb 2025

Recent future growth updates

Recent updates

Unpleasant Surprises Could Be In Store For Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) Shares

Feb 09
Unpleasant Surprises Could Be In Store For Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) Shares

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Dec 17
Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Earnings and Revenue Growth Forecasts

NSEI:GLENMARK - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027168,08921,58511,361N/A11
3/31/2026150,78017,6588,362N/A12
3/31/2025134,75713,986-4,150N/A9
12/31/2024139,608-2,002N/AN/AN/A
9/30/2024130,799-10,183-20,772-13,441N/A
6/30/2024128,612-15,732N/AN/AN/A
3/31/2024126,454-18,990-11,638-2,654N/A
12/31/2023131,575-7,640N/AN/AN/A
9/30/2023137,510-1,2633027,192N/A
6/30/2023136,1442,546N/AN/AN/A
3/31/2023116,556-1,6971766,254N/A
12/31/2022126,3558,811N/AN/AN/A
9/30/2022123,4518,305-217,689N/A
6/30/2022121,1738,277N/AN/AN/A
3/31/2022123,0499,4173,18511,087N/A
12/31/2021122,10310,202N/AN/AN/A
9/30/2021118,24810,4645,41112,490N/A
6/30/2021116,14410,226N/AN/AN/A
3/31/2021109,4399,7003,56511,312N/A
12/31/2020107,7789,565N/AN/AN/A
9/30/2020107,4458,9923,94512,296N/A
6/30/2020106,6299,207N/AN/AN/A
3/31/2020106,5737,7604,61013,924N/A
12/31/2019104,3707,173N/AN/AN/A
9/30/2019102,5646,4281,27113,254N/A
6/30/2019100,2277,680N/AN/AN/A
3/31/201998,6559,25087013,242N/A
12/31/201895,5328,863N/AN/AN/A
9/30/201892,0188,721N/AN/AN/A
6/30/201889,0576,716N/AN/AN/A
3/31/201890,7448,039N/A16,481N/A
12/31/201791,9086,420N/AN/AN/A
9/30/201795,05510,083N/AN/AN/A
6/30/201794,89610,233N/AN/AN/A
3/31/201790,7949,160N/A6,574N/A
12/31/201689,31610,402N/AN/AN/A
9/30/201681,7497,508N/AN/AN/A
6/30/201678,4147,292N/AN/AN/A
3/31/201675,7327,021N/A3,448N/A
12/31/201570,3005,697N/AN/AN/A
9/30/201569,5305,141N/AN/AN/A
6/30/201567,2444,814N/AN/AN/A
3/31/201565,5614,753N/A4,817N/A
12/31/201464,8915,078N/AN/AN/A
9/30/201463,9836,092N/AN/AN/A
6/30/201461,8975,984N/AN/AN/A
3/31/201459,4505,423N/A8,537N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLENMARK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).

Earnings vs Market: GLENMARK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GLENMARK is expected to become profitable in the next 3 years.

Revenue vs Market: GLENMARK's revenue (9.2% per year) is forecast to grow slower than the Indian market (10.6% per year).

High Growth Revenue: GLENMARK's revenue (9.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GLENMARK's Return on Equity is forecast to be low in 3 years time (18.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/22 21:13
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Glenmark Pharmaceuticals Limited is covered by 54 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Ganeshram JayaramanAvendus Spark